United virus: the oncolytic tag-team against cancer!
There is an urgent need for innovative therapeutic strategies to treat aggressive metastatic cancers that are incurable with standard therapeutic approaches. Novel treatment strategies like oncolytic virotherapy have led, in some cases, to impressive effects on disease progression in human trials, suggesting that approval of an oncolytic virus therapeutic is on the horizon. While combinations of oncolytic viruses with small molecules are already being tested and have shown promise, we propose that even greater therapeutic synergies could be achieved through rational design of complementary virus therapeutics. In this review, we discuss rational chemical and biological combination strategies to enhance oncolytic virotherapy highlighting the promising combination of vaccinia and vesicular stomatitis oncolytic viruses.
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada K1H 8L6.
Fabrice
F
Le Boeuf
John C
JC
Bell
D000818:Animals; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy* / Q000821:virology; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses; D014616:Vaccinia virus / Q000235:genetics / Q000502:physiology; D018116:Vesiculovirus / Q000235:genetics / Q000502:physiology